Skip to main content
. 2020 Jun 1;9(6):1677. doi: 10.3390/jcm9061677

Table 2.

Main studies evaluating clinical and pathologic characteristics of patients with NET G−3.

Study, Year Number of Patients Median of Age (Years) Tumor Sites Metastatic State (%) Median Ki−67 (%) Median Survival (Months)
Velayoudom-Céphise et al. [3], 2013 12 56 Pancreas, non-digestive sites 100 21 41
Heetfeld et al. [12], 2015 37 52 Pancreas, rectum, stomach, small bowel 62 30 99
Basturk et al. [2], 2015 19 54 Pancreas 67 40 54
Scoazec et al. [32], 2017 21 NA Pancreas, colorectal, stomach, small bowel NA 35 NA
Hijioka et al. [13], 2017 21 63 Pancreas 71 29 42

NA: non-available.